Notice of Results
London, February 8, 2022 - Hikma Pharmaceuticals PLC (Hikma, Group), will announce its preliminary financial results for the year ended 31 December 2021 on Thursday 24 February 2022.
A recording of the presentation will be available on the Group's website at www.hikma.com from 7:00am GMT. Hikma will also hold a live Q&A conference call for analysts at 9:30am GMT, and a recording will be made available on the Company's website.
To join via conference call please dial:
United Kingdom: 0800 640 6441
United Kingdom (local): 020 3936 2999
All other locations: +44 20 3936 2999
Access code: 446040
For further information please contact Tiina Lugmayer - tlugmayer@hikma.com .
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
|
Susan Ringdal EVP, Strategic Planning and Global Affairs |
+44 (0)20 7399 2760/ +44 (0)7776 477050 |
|
Guy Featherstone Senior Investor Relations Manager |
+44 (0)20 3892 4389/ +44 (0)7795 896738 |
|
Layan Kalisse Investor Relations Analyst |
+44 (0)20 7399 2788/ +44 (0)7970 709912 |
Teneo
Charles Armitstead +44 (0)7703 330 269
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 5 minutes ago Marshalls
- 15 minutes ago Bytes Technology Group
- 31 minutes ago PZ Cussons
- 1 hour ago Howden Joinery Group
- 1 hour ago Tatton Asset Management